tradingkey.logo

Indivior PLC

INDV
查看詳細走勢圖
36.160USD
-0.190-0.52%
收盤 12/24, 16:00美東報價延遲15分鐘
4.52B總市值
36.76本益比TTM

Indivior PLC

36.160
-0.190-0.52%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.52%

5天

+1.74%

1月

+9.24%

6月

+163.36%

今年開始到現在

+190.91%

1年

+201.58%

查看詳細走勢圖

TradingKey Indivior PLC股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Indivior PLC當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名22/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價37.86。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Indivior PLC評分

相關信息

行業排名
22 / 158
全市場排名
59 / 4562
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 7 分析師
買入
評級
37.857
目標均價
+3.43%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Indivior PLC亮點

亮點風險
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
業績高增長
公司營業收入穩步增長,連續3年增長31.85%
業績轉盈
公司業績轉盈,最新年度盈利美元
估值高估
公司最新PE估值36.76,處於3年歷史高位
機構加倉
最新機構持股118.02M股,環比增加2.08%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉3.44M股

Indivior PLC新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Indivior PLC簡介

Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
公司代碼INDV
公司Indivior PLC
CEOCiaffoni (Joseph J)
網址https://www.indivior.com/en

常見問題

Indivior PLC(INDV)的當前股價是多少?

Indivior PLC(INDV)的當前股價是 36.160。

Indivior PLC 的股票代碼是什麼?

Indivior PLC的股票代碼是INDV。

Indivior PLC股票的52週最高點是多少?

Indivior PLC股票的52週最高點是38.000。

Indivior PLC股票的52週最低點是多少?

Indivior PLC股票的52週最低點是7.620。

Indivior PLC的市值是多少?

Indivior PLC的市值是4.52B。

Indivior PLC的淨利潤是多少?

Indivior PLC的淨利潤為2.00M。

現在Indivior PLC(INDV)的股票是買入、持有還是賣出?

根據分析師評級,Indivior PLC(INDV)的總體評級為買入,目標價格為37.857。

Indivior PLC(INDV)股票的每股收益(EPS TTM)是多少

Indivior PLC(INDV)股票的每股收益(EPS TTM)是0.984。
KeyAI